**Date:** 16 October 2026

# CRITICAL RECALL

## Swisse Nutra+ Andro Max 30 tabs (AUST L 330145)

### Batch/Lot Number(s): All batches within expiry

**TGA Ref:** RC-2026-RN-00749-1

Dear Megan,

Swisse Wellness Pty Ltd, following agreement with the Therapeutic Goods Administration (TGA), is conducting a recall of all batches that are still within expiry for the above listed medicine **Swisse Nutra+ Andro Max 30 tabs.** The product has been supplied to Rener Health.

| | |
|---|---|
| **WHAT IS THE PROBLEM?** | • Since 2019, listed medicines containing *Andrographis paniculata* (Andrographis) for supply in Australia have been required to carry a label warning about the risk of allergic reactions including severe reactions such as anaphylaxis.<br>• However, despite these warnings, the TGA has continued to receive a sustained high number of reports of anaphylaxis associated with Andrographis-containing listed medicines, which are considered low-risk medicines.<br>• Andrographis has now been removed from the *Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2026*. This means the ingredient is no longer available for use in new listed (low risk) medicines for supply in Australia.<br>• Further information on this decision is available at https://www.tga.gov.au/news/news-articles/andrographis-removed-listed-medicines-framework-because-allergy-risk |
| **WHAT IS THE HAZARD/RISK?** | • Anaphylaxis is the most severe type of allergic reaction and is a medical emergency.<br>• It requires immediate treatment with adrenaline (epinephrine). Delayed treatment can be life-threatening.<br>• Andrographis-related anaphylaxis reactions are unpredictable and can happen the first time someone takes it, or after taking it previously without any issue. |

| | |
|---|---|
| **WHAT SHOULD YOU DO?** | **Distributors/retailers**<br>• As advised earlier prior to this notice, inspect your stock on hand **immediately** and quarantine all stock of Swisse Nutra+ Andro Max 30 tabs on hand to prevent further use or distribution.<br>• Ensure relevant staff members are informed of this recall.<br>• If you have supplied or transferred any of the above product(s) to another facility or organisation, provide that facility with a copy of this letter **immediately.**<br>• Place this letter in a prominent position for at least one month.<br>• Retailers are recommended to place the 'Public Notice' attached to this letter in their storefront to alert consumers about the recall.<br>• **Complete the Customer Response Form, even if you do not have any affected stock**<br>• **Submit your form via MyRener Recall Returns Upload. The Customer Service Team at Rener Health Products will respond with further instructions. All credits will be processed once returned stock has been assessed. A credit will be placed on your Rener Health Products account.**<br><br>**Consumers**<br>• Consumers are advised that if they have the above product, to not use it.<br>• Consumers can contact Swisse Wellness on **1800 794 773 or email** recall@swisse.com.au to arrange the return and refund of the product. Swisse Wellness will provide return instructions and will cover the cost of returning the product.<br>• If someone is suspected of having anaphylaxis, call for emergency medical help immediately by dialling '000'. |
| **HOW WILL THIS BE RESOLVED?** | • The affected product will be discontinued and no longer available for sale/supply. |
| **CONTACT INFORMATION** | For questions regarding this letter, please contact:<br><br>Heidi Moss<br>Phone: +61 (0) 417 475 578<br>Email: Heidi.moss@hh.global |

Thank you for your assistance in helping us to manage this recall.

Swisse Wellness Pty Ltd sincerely regrets any inconvenience caused to your organisation.

**Swati Prasad**
**Managing Director ANZ**